Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
May 19, 2021
Redoxis

Redoxis in collaborative project to study inflammation in vascular disease

Redoxis in collaborative project to study inflammation in vascular disease

-
Redoxis
-
May 19, 2021

We are happy to announce that Redoxis AB is a partner in a research project called “Targeting he melanocortin system as a novel strategy to reduce inflammation during vascular disease” led by Senior Lecturer Liza Ljungberg, School of Medical Sciences at Örebro University. The project was funded by a research grant of SEK 4 million from The Knowledge Foundation, funding research and competence development at Swedish universities. Redoxis will contribute to the project, that is planned to start 1st of July 2021, with expertise in preclinical drug development and efficacy assessment in both disease models and functional assays.

“Participating in this project is in line with Redoxis aim to continuously expand competence area, implement new clinically relevant models and stay closely connected with academic research in our quest to be the best contract research organization in preclinical inflammatory research” says Malin Hultqvist Hopkins, CEO of Redoxis AB

The project is a collaboration between Örebro University, SynAct Pharma AB and Redoxis AB.

Last updated:
May 19, 2021

Redoxis

Redoxis performs tailor-made preclinical studies combining dedication, experience and agility to provide reliable results to your project.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

We are happy to announce that Redoxis AB is a partner in a research project called “Targeting he melanocortin system as a novel strategy to reduce inflammation during vascular disease” led by Senior Lecturer Liza Ljungberg, School of Medical Sciences at Örebro University. The project was funded by a research grant of SEK 4 million from The Knowledge Foundation, funding research and competence development at Swedish universities. Redoxis will contribute to the project, that is planned to start 1st of July 2021, with expertise in preclinical drug development and efficacy assessment in both disease models and functional assays.

“Participating in this project is in line with Redoxis aim to continuously expand competence area, implement new clinically relevant models and stay closely connected with academic research in our quest to be the best contract research organization in preclinical inflammatory research” says Malin Hultqvist Hopkins, CEO of Redoxis AB

The project is a collaboration between Örebro University, SynAct Pharma AB and Redoxis AB.

Last updated:
May 19, 2021

Redoxis

Redoxis performs tailor-made preclinical studies combining dedication, experience and agility to provide reliable results to your project.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail